HF
TVTX icon

HRT Financial’s Travere Therapeutics TVTX Stock Holding History

HRT Financial’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.6M Buy
+121,200
New +$3.62M 0.01% 1201

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HRT Financial's TVTX Position: Q1 2026 in Review

HRT Financial opened a new position in Travere Therapeutics (TVTX) in Q1 2026: 173,612 shares worth $5.16M. The stake represents 0.01% of the portfolio and ranks #979 among its holdings. This is a return to the name: HRT Financial previously reported a position in TVTX as recently as Q1 2025.

HRT Financial first reported a position in TVTX in Q4 2019 and has held it in 11 quarters since. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • HRT Financial held 173,612 shares of Travere Therapeutics worth $5.16M as of Q1 2026.
  • Travere Therapeutics was a new HRT Financial position in Q1 2026.
  • Travere Therapeutics made up 0.01% of HRT Financial's portfolio in Q1 2026, its #979 holding.
  • HRT Financial first reported a position in Travere Therapeutics in Q4 2019 and has held it in 11 quarters since.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.